About: Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans
Creator	Wong, Chi-Huey Wu, Chung-Yi Jan, Jia-Tsrong Butler, Michael Dionne, Ben Huang, Ming-Hsi Lin, Shih-Chang Wu, Suh-Chin
topic	covid:3bad4716622640d66aad1bf65067abc5b5a2cb01#this
Source	PMC
abstract	Highly pathogenic avian influenza H5N1 viruses can result in poultry and occasionally in human mortality. A safe and effective H5N1 vaccine is urgently needed to reduce the pandemic potential. Hemagglutinin (HA), a major envelope protein accounting for approximately 80% of spikes in influenza virus, is often used as a major antigen for subunit vaccine development. In this study, we conducted a systematic study of the immune response against influenza virus infection following immunization with recombinant HA proteins expressed in insect (Sf9) cells, insect cells that contain exogenous genes for elaborating N-linked glycans (Mimic) and mammalian cells (CHO). While the antibody titers are higher with the insect cell derived HA proteins, the neutralization and HA inhibition titers are much higher with the mammalian cell produced HA proteins. Recombinant HA proteins containing tri- or tetra-antennary complex, terminally sialylated and asialyated-galactose type N-glycans induced better protective immunity in mice to lethal challenge. The results are highly relevant to issues that should be considered in the production of fragment vaccines.
has issue date	2013-06-14(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0066719
bibo:pmid	23799128
has license	cc-by
sha1sum (hex)	3bad4716622640d66aad1bf65067abc5b5a2cb01
schema:url	https://doi.org/10.1371/journal.pone.0066719
resource representing a document's title	Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans
has PubMed Central identifier	PMC3682957
has PubMed identifier	23799128
schema:publication	PLoS One
resource representing a document's body	covid:3bad4716622640d66aad1bf65067abc5b5a2cb01#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/3bad4716622640d66aad1bf65067abc5b5a2cb01
is schema:about of	named entity 'MANNOSE' named entity 'N-GLYCANS' named entity 'cells' named entity 'conducted' named entity 'titers' named entity 'virus' covid:arg/3bad4716622640d66aad1bf65067abc5b5a2cb01 named entity 'MAMMALIAN' named entity 'VACCINES' named entity 'DIFFERENT' named entity 'GLYCANS' named entity 'EXPRESSED' named entity 'CELLS' named entity 'HIGHER' named entity 'PROTEINS' named entity 'MICE' named entity 'BETTER' named entity 'EXOGENOUS' named entity 'VACCINE DEVELOPMENT' named entity 'HIGHLY PATHOGENIC AVIAN INFLUENZA' named entity 'CONTAINING' named entity 'HEMAGGLUTININ' named entity 'SUBUNIT VACCINE' named entity 'IMMUNE RESPONSE' named entity 'PANDEMIC' named entity 'INFLUENZA VIRUS' named entity 'IMMUNITY' named entity 'RECOMBINANT' named entity 'COMPLEX TYPE' named entity 'HIGH' named entity 'RELEVANT' named entity 'STUDY' named entity 'INHIBITION' named entity 'RESULT' named entity 'INFECTION FOLLOWING IMMUNIZATION' named entity 'PROTEIN ' named entity 'EFFECTIVE' named entity 'ACCOUNTING' named entity 'PROTECTIVE IMMUNITY' named entity 'HUMAN MORTALITY' named entity 'ANTIGEN' named entity 'MUCH' named entity 'RESULTS' named entity 'TRI' named entity 'VACCINE' named entity 'INSECT CELL' named entity 'TO REDUCE' named entity 'COMPLEX' named entity 'NEEDED' named entity 'INDUCED' named entity 'N-GLYCANS' named entity 'ENVELOPE PROTEIN' named entity 'OCCASIONALLY' named entity 'DERIVED' named entity 'VIRUS INFECTION' named entity 'USED' named entity 'FRAGMENT' named entity 'RECOMBINANT' named entity 'POULTRY' named entity 'CONTAIN' named entity 'ISSUES' named entity 'ANTIBODY TITERS' named entity 'A MAJOR' named entity '80%' named entity 'CONTAINING' named entity 'ELICITED BY' named entity 'PROTEINS' named entity 'POTENTIAL' named entity 'INSECT' named entity 'LETHAL' named entity 'HEMAGGLUTININ' named entity 'CHALLENGE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software